STOCKIFY
invest early

US PRIVATE EQUITY

Neuralink

Opening soon

Develops brain-computer interface devices for medical use.

Sector: Healthcare / Medical Devices | Head office: Austin, TX | Founded: 2016 | IPO status: Private, no listing announced

LATEST VALUATION
$9.62B
Series E-LV, 2 Jun 2025, post-money, $50.5 a share

REVENUE
$20M
Estimated, range $5M - 25M

ABOUT

Neuralink develops brain-computer interface devices that translate neural signals into actions. It runs clinical trials with patients who have spinal cord injury or amyotrophic lateral sclerosis. The company has reported implants as early as January 2024.

LATEST FUNDING ROUNDS

Round	Date	Amount raised	Company value
Series D-LV	22 Nov 2023	$161.62M	$3.49B
Series E	2 Jun 2025	$324.5M	$9.62B
Series E-LV	2 Jun 2025	$324.5M	$9.62B
Equity	May 2026	-	-

LEADERSHIP AND INVESTORS

Leadership Dongjin Seo (Founder), Elon Musk (Chief Executive Officer), Jared Birchall (Chief Executive Officer), Jared John Birchall (CEO)

Investors Valor Equity Partners, Founders Fund, K5 Global, Craft Ventures, DFJ Growth, Vy Capital, S32, Draper Fisher Jurvetson Management

RISKS

- You could lose money. Private companies can fall in value, and late-stage rounds are priced for strong growth.
- Your money is locked in. There is no daily price and no guaranteed way to sell.
- The listing could take years, or never happen.
- Information is limited: private companies publish far less than listed ones.

Register interest: https://stockify.net.in/us-private-equity/neuralink Data as of 25 Nov 2026

Private company figures are estimates from public reports and company announcements, not audited filings. This page is information, not advice or an offer. Past valuations do not predict future returns.